Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMD303 plus PD-1 inhibitor in advanced solid tumors
ACTRN12626000450314Phase 2Not yet recruiting
- Sponsor
- Catalysis Therapeutics
- Start
- Jan 2027
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of IMD303 and nivolumab in Nonhematologic neoplasms, melanoma, renal cell carcinoma (RCC) and 1 more (2 arms), sponsored by Catalysis Therapeutics. Primary endpoints: Adverse events, treatment-related adverse events, and serious adverse events, Overall response rate and 1 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
IMD303nivolumab
03
Conditions
Nonhematologic neoplasmsmelanomarenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12626000450314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000450314.